Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Mar;117(5):817–822. doi: 10.1111/j.1476-5381.1996.tb15266.x

Suppression of reperfusion-induced arrhythmias with combined administration of 5-HT2 and thromboxane A2 antagonists.

L A Shaw 1, S J Coker 1
PMCID: PMC1909424  PMID: 8851496

Abstract

1. The effects of the 5-HT2 antagonist, ICI 170,809 and the thromboxane A2 antagonist, ICI 192,605, given alone and in combination (n = 12 per group), were examined in anaesthetized rats. Haemodynamics and arrhythmias induced by permanent coronary artery occlusion or by reperfusion after 5 min of ischaemia were monitored. 2. In a study on reperfusion-induced arrhythmias, the only significant effect of ICI 170,809 (1 mg kg-1, i.v.) was a reduction in the number of ventricular premature beats (VPBs). ICI 192,605 (1 mg kg-1 min-1, i.v.) did not alter reperfusion-induced arrhythmias. However, in combination, when compared with controls, these drugs caused significant reductions in the incidence of ventricular tachycardia (VT), 100% to 58%; ventricular fibrillation (VF), 92% to 33%; and the mortality due to sustained VF, 67% to 17%. There was also a significant reduction in the number of VPBs following reperfusion. 3. In a second study with lower doses of drugs, ICI 170,809 (0.3 mg kg-1) and ICI 192,605 (0.3 mg kg-1 min-1) had no significant effects on reperfusion-induced arrhythmias either alone or in combination. 4. A third study examined the effects of the higher doses of the drugs on ischaemia-induced arrhythmias. Neither drug alone, nor in combination, altered the incidence of ischaemia-induced VT, VF, the mortality, or the number of VPBs. 5. These results indicate that, in contrast to the administration of either drug alone, combined administration of a 5-HT2 antagonist and a thromboxane A2 antagonist caused marked suppression of reperfusion-induced but not ischaemia-induced arrhythmias.

Full text

PDF
817

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton J. H., Benedict C. R., Fitzgerald C., Raheja S., Taylor A., Campbell W. B., Buja L. M., Willerson J. T. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 1986 Mar;73(3):572–578. doi: 10.1161/01.cir.73.3.572. [DOI] [PubMed] [Google Scholar]
  2. Ashton J. H., Ogletree M. L., Michel I. M., Golino P., McNatt J. M., Taylor A. L., Raheja S., Schmitz J., Buja L. M., Campbell W. B. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation. 1987 Oct;76(4):952–959. doi: 10.1161/01.cir.76.4.952. [DOI] [PubMed] [Google Scholar]
  3. Ashton J. H., Schmitz J. M., Campbell W. B., Ogletree M. L., Raheja S., Taylor A. L., Fitzgerald C., Buja L. M., Willerson J. T. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists. Circ Res. 1986 Nov;59(5):568–578. doi: 10.1161/01.res.59.5.568. [DOI] [PubMed] [Google Scholar]
  4. Barnes C. S., Coker S. J. Failure of nitric oxide donors to alter arrhythmias induced by acute myocardial ischaemia or reperfusion in anaesthetized rats. Br J Pharmacol. 1995 Jan;114(2):349–356. doi: 10.1111/j.1476-5381.1995.tb13233.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coker S. J., Ellis A. M. Ketanserin and ritanserin can reduce reperfusion-induced but not ischaemia-induced arrhythmias in anaesthetised rats. J Cardiovasc Pharmacol. 1987 Oct;10(4):479–484. doi: 10.1097/00005344-198710000-00015. [DOI] [PubMed] [Google Scholar]
  6. Coker S. J. Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J Mol Cell Cardiol. 1984 Jul;16(7):633–641. doi: 10.1016/s0022-2828(84)80627-6. [DOI] [PubMed] [Google Scholar]
  7. Coker S. J., Parratt J. R. AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds. Br J Pharmacol. 1985 Sep;86(1):259–264. doi: 10.1111/j.1476-5381.1985.tb09457.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coker S. J., Parratt J. R., Ledingham I. M., Zeitlin I. J. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature. 1981 May 28;291(5813):323–324. doi: 10.1038/291323a0. [DOI] [PubMed] [Google Scholar]
  9. De Clerck F. F., Herman A. G. 5-hydroxytryptamine and platelet aggregation. Fed Proc. 1983 Feb;42(2):228–232. [PubMed] [Google Scholar]
  10. Docherty J. R. Investigations of cardiovascular 5-hydroxytryptamine receptor subtypes in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1988 Jan;337(1):1–8. doi: 10.1007/BF00169468. [DOI] [PubMed] [Google Scholar]
  11. Ellis A. M., Coker S. J. Contribution of antiplatelet activity to the effects of 5-HT2 receptor antagonists on reperfusion-induced arrhythmias in anaesthetized rats. Eur J Pharmacol. 1992 Aug 14;219(1):97–104. doi: 10.1016/0014-2999(92)90585-r. [DOI] [PubMed] [Google Scholar]
  12. Haerem J. W. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease. Atherosclerosis. 1972 Mar-Apr;15(2):199–213. doi: 10.1016/0021-9150(72)90070-6. [DOI] [PubMed] [Google Scholar]
  13. Leprán I., Parratt J. R., Szekeres L., Wainwright C. L. The effects of metoprolol and dazmegrel, alone and in combination, on arrhythmias induced by coronary artery occlusion in conscious rats. Br J Pharmacol. 1985 Sep;86(1):229–234. doi: 10.1111/j.1476-5381.1985.tb09453.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Millson D. S., Jessup C. L., Swaisland A., Haworth S., Rushton A., Harry J. D. The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers. Br J Clin Pharmacol. 1992 Mar;33(3):281–288. doi: 10.1111/j.1365-2125.1992.tb04036.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mullane K. M., Bradley G., Moncada S. The interactions of platelet-derived mediators on isolated canine coronary arteries. Eur J Pharmacol. 1982 Oct 15;84(1-2):115–118. doi: 10.1016/0014-2999(82)90166-2. [DOI] [PubMed] [Google Scholar]
  16. Saxena P. R., Villalón C. M. 5-Hydroxytryptamine: a chameleon in the heart. Trends Pharmacol Sci. 1991 Jun;12(6):223–227. doi: 10.1016/0165-6147(91)90556-8. [DOI] [PubMed] [Google Scholar]
  17. Siess W. Molecular mechanisms of platelet activation. Physiol Rev. 1989 Jan;69(1):58–178. doi: 10.1152/physrev.1989.69.1.58. [DOI] [PubMed] [Google Scholar]
  18. Steen V. M., Holmsen H. Current aspects on human platelet activation and responses. Eur J Haematol. 1987 May;38(5):383–399. doi: 10.1111/j.1600-0609.1987.tb01434.x. [DOI] [PubMed] [Google Scholar]
  19. Vandeplassche G., Hermans C., Van Dael L., Wouters L., De Clerck F. Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis. J Cardiovasc Pharmacol. 1993 Jan;21(1):56–69. doi: 10.1097/00005344-199301000-00009. [DOI] [PubMed] [Google Scholar]
  20. Wainwright C. L., Parratt J. R. The effect of beta-adrenoceptor blockade and of thromboxane synthetase inhibition, alone and in combination, on arrhythmias resulting from myocardial ischemia. Adv Myocardiol. 1985;6:573–584. [PubMed] [Google Scholar]
  21. Walker M. J., Curtis M. J., Hearse D. J., Campbell R. W., Janse M. J., Yellon D. M., Cobbe S. M., Coker S. J., Harness J. B., Harron D. W. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res. 1988 Jul;22(7):447–455. doi: 10.1093/cvr/22.7.447. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES